Scientists and engineers at UC Santa Barbara and other researchers have developed a nanoparticle that can attack plaque –– a major cause of cardiovascular disease. The new development is described in a recent issue of the Proceedings of the National Academy of Sciences.

A team of international researchers – including scientists from the McGill University Health Centre (MUHC) and McGill University – have discovered that having high levels of particular protein puts patients at increased risk of developing cardiovascular disease. The results of the study were so conclusive that the clinical trial had to be stopped before its scheduled completion date.

A team of researchers from Wake Forest University, the National Institutes of Health and other institutions has discovered a previously undetected chemical process within the oxygen-carrying molecule hemoglobin that could have far-reaching implications for the treatment of cardiovascular diseases.

Scientists report that when people with a transplanted kidney take fluvastatin, a drug against cardiovascular disease, their response to the drug is not influenced by their genetic composition.

University of Minnesota researchers have discovered that treating people who have early cardiovascular abnormalities, but show no symptoms of cardiovascular disease, can slow progression and even reverse damage to the heart and blood vessels.

Anticoagulants (e.g., warfarin) and antiplatelet drugs (e.g., acetylsalicylic acid) are key therapeutic agents in the treatment of cardiovascular diseases.